Laurel A. Habel, PhD

Laurel Habel, PhD, has been a Research Scientist at Kaiser’s Division of Research since 1996. She obtained her MPH in Epidemiology from UCLA in 1980 and her PhD in Epidemiology from the University of Washington, Seattle in 1996. Dr. Habel’s research interests include the etiology and progression of cancer and precursor lesions for cancer, mammographic density and other biomarkers of disease risk or progression, and the association between use of medications and cancer risk. She is the Principal Investigator or site Principal Investigator on several federally-funded research projects.

Current Positions:

	Research Scientist, Division of Research, Kaiser Permanente, Northern California
	Lecturer in Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA

Primary Research Interests:

	Breast cancer etiology and progression
	Etiology and progression of precursor lesions for cancer
	Mammographic density and other biomarkers of disease risk or progression
	Use of medication and cancer risk

Current and Recently Completed Research Projects:

	CRN II: Clinical and Pathologic Predictors of Recurrence After DCIS (NCI, Project Leader)
	DCIS: Mammographic Freatures and Prognosis (NCI, Principal Investigator)
	Mammographic Density and Breast Cancer After DCIS (NCI, Principal Investigator)
	Mammographic Density in a Multi-ethnic Cohort (NCI, Principal Investigator)
	Tumor Gene Expression and Breast Cancer Survival (Genomic Health, Inc, Principal Investigator)
	Proteomic Prediction of Breast Cancer Risk: A Cohort Study (DoD, site PI)
	Pharmaceuticals and Cancer (NCI, Principal Investigator)
	The Association between PPAR Gamma Ligands and Colonic Neoplasia (NCI, site PI)

Selected Publications:

	Habel LA, Stanford JL. Hormone receptors and breast cancer. Epidemiol Rev 1993;15:209-19.
	Bairati I, Sherman KJ, McKnight B, Habel LA, Van Den Eeden SK, Stergachis A, Daling JR. Diet and genital warts: a case-control study. Sex Trans Dis 1994;21:149-53.
	Habel LA, Stanford JL, Vaughan T, Rossing MA, Voigt L, Daling JR, Weiss NS. Occupation and breast cancer in middle-aged women. J Occup Environ Med 1995;37:349-56.
	Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
	Carter JJ, Wipf GC, Hagensee ME, McKnight B, Habel LA, Lee S-K, Kuypers J, Kiviat N, Daling JR, Koutsky LA, Watts H, Homes KK, Galloway DA. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995;172:11-8.
	Rossing MA, Stanford JL, Weiss NS, Habel LA. Oral contraceptive use and risk of breast cancer in middle-aged women. Am J Epidemiol 1996;144:161-4.
	Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS. Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 1997;225:69-75.
	Habel LA, Van Den Eeden SK, Sherman KJ, McKnight B, Stergachis A, Daling JR. Risk factors for incident and recurrent condylomata acuminata among females: a population-based study. Sex Transm Dis 1998;25:285-92.
	Van Den Eeden SK, Habel LA, Sherman KJ, McKnight B, Stergachis A, Daling JR. Risk factors for incident and recurrent condylomata acuminata among males: a population-based study. Sex Transm Dis 1998;25:278-84.
	Habel LA, Daling JR, Newcomb PA, Self SG, Porter PL, Stanford JL, Seidel K, Weiss NS. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 1998;7:689-96.
	Habel LA, Bull SA, Friedman GD. Barbiturates, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1049-50.
	Friedman GD, Habel LA. Barbiturates and lung cancer: a re-evaluation. Int J Epidemiol 1999;28:375-9.
	Habel LA, Van Den Eeden SK, Friedman GD. Body size, age at shaving initiation, and prostate cancer in a large, multi-racial cohort. Prostate 2000;43:136-43.
	Habel LA, Levin TR, Friedman GD. Cimetidine use and risk of breast, prostate, and other cancers. Pharmacoepidemiol Drug Saf 2000;9:149-55.
	Habel LA. Epidemiology of ductal carcinoma in situ. Semin Breast Dis 2000;3:187 199.
	Shibata A, Longacre TA, Puligandla B, Parsonnet J, Habel LA. Histologic classification of gastric adenocarcinoma for epidemiologic research: concordance between pathologists. Cancer Epidomiol Biomarkers Prev 2001;10:75-8.
	Corley DA, Levin TR, Habel LA, Buffler PA. Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology 2002;29:182-7.
	Shibata A, Garcia MI, Longacre TA, Parsonnet J, Puligandla B, Davis ER, Vogelman JH, Orentriech, Habel LA. P53 gene mutation and gastric adenocarcinoma in relation Helicobacter pylori serology and tumor histologic type. Carcinogenesis 2002; 23:419-24.
	Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multi-racial cohort. Cancer Causes Control 2002;13:427-34.
	Efird JT, Friedman GD, Habel L, Tekawa IS, Nelson LM. Risk of subsequent cancer following invasive or in situ squamous cell skin cancer. Ann Epidemiol 2002;12:469-75.
	Habel LA, Dignam JJ, Land SR, Salane M, Capra AM, Julian TB. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst. 2004;6;96:1467-72.
	Habel LA, Schaefer CA, Levine P, Bhat AK, Elliott G. Treatment with stimulants among youths in a large California health plan. Division of Research, Kaiser Permanente, Oakland, California. J Child Adolesc Psychopharmacol 2005;15:62-7.
	Habel LA, Pressman A, Ettinger B, Sidney S, Suh-Burgmann B, Fehrenbacher L, Quesenberry CP. Use of raloxifene among women with a history of breast cancer. Breast Cancer Res Treat 2006;96:123-9.
	Corley DA, Levin TR, Habel LA, Buffler PA. Barrett's esophagus and medications that relax the lower esophageal sphincter. Am J Gastroenterol 2006;101:937-44.
	Caan BJ, Emond JA, Natarajan L, Castillo A, Gunderson EP, Habel L, Jones L, Newman VA, Rock CL, Slattery ML, Stefanick ML, Sternfeld B, Thomson CA, Pierce JP. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat 2006;99:47-57.
	Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8:R25.
	Corley DA, Levin TR, Habel LA, Buffler PA. Barrett's esophagus and medications that relax the lower esophageal sphincter. Am J Gastroenterol 2006;101:937-44.
	Enger SM, Van Den Eeden SK, Sternfeld B, Loo RK, Quesenberry CP Jr, Rowell S, Sadler MC, Schaffer DM, Habel LA, Caan BJ. California Men's Health Study (CMHS): A multiethnic cohort in a managed care setting. BMC Public Health 2006;6:172.